<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642679</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001975</org_study_id>
    <nct_id>NCT02642679</nct_id>
  </id_info>
  <brief_title>Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects</brief_title>
  <acronym>STSG</acronym>
  <official_title>Evaluation of Opticell Ag (Chitosan Based Dressing) on Split-Thickness Skin Graft (STSG) Donor Sites in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medline Industries</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this single center, prospective case series is to evaluate the effective
      management of split-thickness skin graft donor site wounds using Opticell Ag (Chitosan-based
      dressing).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>Assessed up to 14 days of use</time_frame>
    <description>Pain reported by Subject using a visual analog scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Healing Rate (Re-epithelialization)</measure>
    <time_frame>Assessed up to 14 days of use</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound Healing Quality</measure>
    <time_frame>Assessed up to 1 month of use</time_frame>
    <description>Assessed using the Vancouver scar scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Use</measure>
    <time_frame>Assessed up to 14 days of use</time_frame>
    <description>Assessed by investigators using a 5-point Likert Scale up to 14 days of use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of treatment</measure>
    <time_frame>Assessed up to 1 month of use</time_frame>
    <description>Assessed by investigators using a cost analysis of the treatment comparing all dressings up to 1 month of use</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Split-thickness Skin Graft Donor Sites</condition>
  <arm_group>
    <arm_group_label>Opticell Ag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Opticell Ag</intervention_name>
    <arm_group_label>Opticell Ag</arm_group_label>
    <other_name>Opticell Ag+</other_name>
    <other_name>Opticell Ag Plus Gelling Fiber with Silver</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient status at study site

          -  Subject must be receiving a split-thickness skin graft (STSG)

          -  Wounds must not exceed 10% total body surface area (TBSA)

          -  Any donor site

          -  Ability to comply with necessary wound care/follow up

        Exclusion Criteria:

          -  Subject is pregnant

          -  Subject has been diagnosed with Diabetes

          -  Subject is a smoker

          -  Subject takes steroids

          -  Subject is sensitive and/or allergic to shellfish and/or silver

          -  Wounds that exceed 10% total body surface area (TBSA)

          -  Inability to comply with necessary wound care/follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>December 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Indranil Sinha</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery, Harvard Medical School, Division of Plastic Surgery</investigator_title>
  </responsible_party>
  <keyword>Split-thickness skin graft, donor site, chitosan, dressing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chitosan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
